Literature DB >> 17049192

Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis.

M S El-Ridy1, D M Mostafa, A Shehab, E A Nasr, Sameh Abd El-Alim.   

Abstract

Pyrazinamide liposomes were prepared employing the phospholipid molar ratios; dipalmitoyl phosphatidyl choline (7):cholesterol (2) neutral and dipalmitoyl phosphatidyl choline (7):cholesterol (2):dicetyl phosphate (1) negatively charged. Swelling at 52 degrees C led to higher trapping efficiencies. An optimum sterilizing dose of 25 kGy was exhibited by gamma (gamma)-irradiation. Neutral pyrazinamide liposomes (7:2), swollen for 24 h, were employed in biological evaluation for treatment of mice infected by Mycobacterium tuberculosis. Liposomal pyrazinamide could effect highly significant reduction in bacterial counts (colony forming units/g lung), 10, 20 and 30 days after the last treatment dose. Histopathological examination of mice lungs showed highest severity of infection in drug-free liposomes (control) group > pyrazinamide liposomes > free pyrazinamide 6 days/week. The results indicate high therapeutic efficacy of pyrazinamide liposomes, injected twice weekly, in treatment of M. tuberculosis in mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17049192     DOI: 10.1016/j.ijpharm.2006.09.017

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  10 in total

Review 1.  Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

Authors:  Lauren Willis; Don Hayes; Heidi M Mansour
Journal:  Lung       Date:  2012-01-25       Impact factor: 2.584

Review 2.  Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead.

Authors:  Estefania Grotz; Nancy Tateosian; Nicolas Amiano; Maximiliano Cagel; Ezequiel Bernabeu; Diego A Chiappetta; Marcela A Moretton
Journal:  Pharm Res       Date:  2018-09-20       Impact factor: 4.200

Review 3.  Pharmacologic considerations in use and development of antituberculosis drugs.

Authors:  Geraint Davies
Journal:  Cold Spring Harb Perspect Med       Date:  2014-09-18       Impact factor: 6.915

4.  Gamma-irradiated liposome/noisome and lipogelosome/niogelosome formulations for the treatment of rheumatoid arthritis.

Authors:  Selcan Turker; A Yekta Ozer; Ekrem Kiliç; Meral Ozalp; Seyda Colak; Mustafa Korkmaz
Journal:  Interv Med Appl Sci       Date:  2013-07-04

5.  The effects of gamma irradiation on diclofenac sodium, liposome and niosome ingredients for rheumatoid arthritis.

Authors:  A Yekta Ozer; Selcan Turker; Seyda Colak; Mustafa Korkmaz; Ekrem Kiliç; Meral Ozalp
Journal:  Interv Med Appl Sci       Date:  2013-09-16

Review 6.  Nanobiosystems for Antimicrobial Drug-Resistant Infections.

Authors:  Foteini Gkartziou; Nikolaos Giormezis; Iris Spiliopoulou; Sophia G Antimisiaris
Journal:  Nanomaterials (Basel)       Date:  2021-04-22       Impact factor: 5.076

Review 7.  Nanomedicines as Drug Delivery Carriers of Anti-Tubercular Drugs: From Pathogenesis to Infection Control.

Authors:  Afzal Hussain; Sima Singh; Sabya Sachi Das; Keshireddy Anjireddy; Subramanian Karpagam; Faiyaz Shakeel
Journal:  Curr Drug Deliv       Date:  2019       Impact factor: 2.565

8.  Mannose receptor targeted bioadhesive chitosan nanoparticles of clofazimine for effective therapy of tuberculosis.

Authors:  Datta Maroti Pawde; Matte Kasi Viswanadh; Abhishesh Kumar Mehata; Roshan Sonkar; Suruchi Poddar; Ankita Sanjay Burande; Abhishek Jha; Kiran Yellappa Vajanthri; Sanjeev Kumar Mahto; V N Azger Dustakeer; Madaswamy S Muthu
Journal:  Saudi Pharm J       Date:  2020-10-24       Impact factor: 4.330

Review 9.  Nanocarrier-Based Approaches for the Efficient Delivery of Anti-Tubercular Drugs and Vaccines for Management of Tuberculosis.

Authors:  Amarjitsing Rajput; Satish Mandlik; Varsha Pokharkar
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

10.  Effects of the encapsulation of usnic acid into liposomes and interactions with antituberculous agents against multidrug-resistant tuberculosis clinical isolates.

Authors:  Rafaela S Ferraz-Carvalho; Marcela A Pereira; Leonardo A Linhares; Mariane Cb Lira-Nogueira; Isabella Mf Cavalcanti; Nereide S Santos-Magalhães; Lílian Ml Montenegro
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-04-29       Impact factor: 2.743

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.